
|Articles|August 1, 2003
Urologists may be targeted in second LHRH case
Wilmington, DE-The federal government will likely pursue urologistsin a second round of investigations surrounding the fraudulent marketingand sale of luteinizing hormone-releasing hormone agonists for prostatecancer. Just how far the probe will extend remains a source of debate amonglegal experts familiar with the case.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Individualizing androgen pathway therapy in mCSPC
3
Testosterone deficiency: FAQs from the AUA guideline
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5












